Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...

A new study finds that ursodeoxycholic acid (UDCA) effectively dissolves gallstones in 60% of patients after sleeve ...

对此，Shilpa Medicare的董事总经理Vishnukant Bhutada表示：“我们对SEC的批准感到非常高兴，并期待尽快获得市场授权。我们致力于与监管机构紧密合作，尽快将这一创新疗法带给患者，计划在即将到来的财年内在印度上市。” ...

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the ...

研究人员运用了多种关键技术方法。在纳米囊泡制备方面，通过超声破碎 RAW264.7 细胞，再经一系列处理得到巨噬细胞来源的纳米囊泡（NVs），并将 UDCA 载入其中，进一步修饰得到线粒体靶向的纳米囊泡（UDCA-NVs-TPP） 。在细胞和动物实验中，利用多种细胞模型和 PD 小鼠模型，借助 CCK-8、ABTS ...

根据美国食品药品管理局（FDA）发布的安全警告，患有无肝硬化的原发性胆汁性胆管炎（PBC）的患者使用Ocaliva® （奥贝胆酸）治疗时报告了严重的肝损伤。 Ocaliva 是一种法呢醇 X 受体激动剂，于 2016 年获得加速批准用于治疗 ...

近日，吉利德宣布，欧盟委员会（EC）已有条件批准Seladelpar上市，与熊去氧胆酸（UDCA）联用，治疗对UDCA单药应答不足的原发性胆汁性胆管炎（PBC）患者；或者作为单药，治疗对UDCA治疗不耐受的PBC患者。

Hepatocellular DILI is characterized by inflammation, necrosis, and apoptosis, while cholestatic DILI involves bile plug formation and bile duct paucity. Ursodeoxycholic acid (UDCA), a widely used ...

Ursodeoxycholic acid (UDCA) is the therapeutic agent most widely used for the treatment of cholestatic hepatopathies of diverse etiologies and has been mainly used as a supportive treatment in ...

ALF-agreement, Forte, FORMAS, Swedish Heart Lung Foundation, SciLifeLab / Knut and Alice Wallenbergs Foundation, Swedish Research Council, Swedish Social Insurance Agency SCIFI-PEARL is a nationwide ...

The European Commission also granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults ...